Clearside Biomedical Enters Material Definitive Agreement

TL;DR

**CLSD just signed a big deal, watch for details on what it means for the stock.**

AI Summary

Clearside Biomedical, Inc. (CLSD) filed an 8-K on February 1, 2024, reporting an "Entry into a Material Definitive Agreement" on January 31, 2024. This filing indicates that the company has entered into a significant new contract or partnership, which could impact its future operations and financial performance. For investors, this matters because material agreements often signal new revenue streams, strategic collaborations, or changes in business direction, potentially affecting the stock's valuation.

Why It Matters

This filing signals a new, significant business arrangement for Clearside Biomedical, which could lead to new opportunities or obligations that impact its financial health and stock price.

Risk Assessment

Risk Level: medium — The filing indicates a material agreement but lacks specific details, creating uncertainty about its nature and potential impact, which could be positive or negative.

Analyst Insight

Investors should await further disclosures from Clearside Biomedical regarding the specifics of this material definitive agreement to understand its potential impact on the company's financials and strategic direction before making investment decisions.

Key Numbers

• $0.001 — par value per share (par value of Clearside Biomedical's Common Stock)

Key Players & Entities

• Clearside Biomedical, Inc. (company) — the registrant filing the 8-K
• January 31, 2024 (date) — date of the earliest event reported
• February 1, 2024 (date) — date the 8-K was filed
• 001-37783 (other) — Commission File Number
• CLSD (other) — trading symbol for Common Stock
• $0.001 (dollar_amount) — par value per share of Common Stock

Forward-Looking Statements

• Clearside Biomedical will release further details about the material definitive agreement. (Clearside Biomedical, Inc.) — high confidence, target: 2024-03-31

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share CLSD The Nasdaq Stock Mar
• $250,000 — rting in 2023 through 2028, as follows: $250,000 for 2023 through 2025, $350,000 for 202
• $350,000 — ollows: $250,000 for 2023 through 2025, $350,000 for 2026, $400,000 for 2027 and $500,00
• $400,000 — r 2023 through 2025, $350,000 for 2026, $400,000 for 2027 and $500,000 for 2028. The Mai
• $500,000 — 350,000 for 2026, $400,000 for 2027 and $500,000 for 2028. The Maintenance Fee for 2023

Filing Documents

• clsd-20240131.htm (8-K) — 40KB
• 0000950170-24-009767.txt ( ) — 150KB
• clsd-20240131.xsd (EX-101.SCH) — 24KB
• clsd-20240131_htm.xml (XML) — 5KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On January 31, 2024 (the " Amendment Execution Date "), Clearside Biomedical, Inc. (the " Company "), Emory University (" Emory ") and Georgia Tech Research Corporation (together with Emory, the " Licensor "), entered into an amendment (the " Amendment ") to the Company's License Agreement with Licensor dated July 4, 2012 (as amended, the " License Agreement "), pursuant to which the Company received a worldwide exclusive license to specified patents relating to methods and devices for drug delivery using a microinjector. Pursuant to the Amendment, the parties agreed to reduce the Sublicense Percentage (as defined in the License Agreement) from a low double digit percentage to a high single digit percentage that the Company will pay the Licensor applicable to any fees or payments paid to the Company by any Sublicensee (as defined in the License Agreement) of the Licensed Patents and/or Licensed Technology (each as defined in the License Agreement), on or after July 1, 2023, excluding (i) amounts paid to the Company by a Sublicensee to reimburse the Company for certain research and development costs pursuant to a written agreement between the Company and such Sublicensee, (ii) the value of intellectual property transferred or granted to the Company if necessary or helpful to the development or commercialization of Licensed Products (as defined in the License Agreement) and (iii) amounts paid for shares of the Company's stock. The payment to Licensor of any such Sublicense Percentage is due within 30 days of receipt by the Company of a qualifying payment from a Sublicensee, provided however, with respect to any qualifying payments received by the Company from a Sublicensee after July 1, 2023 but prior to January 1, 2025, the payment to Licensor of any such Sublicensee Percentage is due to Licensor by March 31, 2025. In addition, the parties agreed to a revised annual license maintenance fee due each year, or

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 1, 2024 CLEARSIDE BIOMEDICAL, INC. By: /s/ Charles A. Deignan Name: Charles A. Deignan Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR